Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

BackgroundData on the use of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation are limited. The current study aimed to assess the efficacy of ICIs in EGFR-mutant advanced NSCLC and explore the relevant in...

Full description

Bibliographic Details
Main Authors: Tian Tian, Min Yu, Juan Li, Maoqiong Jiang, Daiyuan Ma, Shubin Tang, Zhiyu Lin, Lin Chen, Youling Gong, Jiang Zhu, Qiang Zhou, Meijuan Huang, You Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
non–small cell lung cancer
immune checkpoint inhibitor
tyrosine kinase inhibitor
epidermal growth factor receptor
resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.739090/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.739090/full

Similar Items